Multiple Sclerosis MS

Multiple sclerosis (MS) is a demyelinating disorder leading to physical and cognitive disability.

MS demyelinating disease

Multiple sclerosis (MS) is a demyelinating disorder leading to physical and cognitive disability. The clinical presentation of MS is heterogeneous, with some patients experiencing isolated attacks (relapsing-remitting MS) and others increasingly worse symptoms (primary progressive MS). Although symptoms may diminish or disappear between attacks, advancing disease leads to permanent neurological deficits. Currently available treatments are only modestly effective and associated with sometimes severe adverse effects.

Multiple sclerosis (MS): microglia cells damage the myelin sheath of neuron axons.

Pathology in the brain

Multiple sclerosis (MS) is a brain disorder characterized by loss of oligodendrocytes, loss of myelin sheats, and neuroinflammation. This leads to progressive axonal damage and formation of plaques/lesions, which strongly correlate with clinical symptoms. The cause of MS is unclear, but genetic variations as well as environmental factors such as viral infections have been proposed to contribute to MS pathogenesis. It is thought that in MS the immune system attacks the myelin sheets, which ultimately leads to deterioration of the nerves.

Sylics offers services with the curpizone mouse model of MS-related de- and remyelination, which allows studying both processes in a single model.

Sylics has epxerience with the administration of  the combination of cuprizone and rapamycin, which  leads to demyelination, without subsequent remyelination.

Immunization with myelin-based self-antigens (e.g. MBP, PLP, MOG) leads to an immune-mediated demyelination phenotype that mimics the core phenotypes of MS.

More information

Please reach out to us if you want to learn more about our Multiple Sclerosis MS solutions. We will contact you within 1 business day.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.